The function of two key targets of insulin action, glycogen synthase and insulin receptor substrate-1 (IRS1), is suppressed by GSK-3, making it a promising drug target for treatment of insulin resistance and diseases of glucose metabolism (e.g., diabetes) [7,8,17,18,19]. Here, IRS1 is linked to diabetes mellitus.